The Initial Indian Experience with Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases

详细信息    查看全文

• 作者：Aditi Bhatt ; Sanket Mehta…
• 关键词：HIPEC ; Indian Experience ; Cytoreductive Surgery ; Peritoneal Metastases
• 刊名：Indian Journal of Surgical Oncology
• 出版年：2016
• 出版时间：June 2016
• 年：2016
• 卷：7
• 期：2
• 页码：160-165
• 全文大小：246 KB
• 参考文献：1.Esquivel J (2014) Current Status and Future Directions of Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Intervent Oncol 360 2(6):E45–E52
  2.Elias D, Goéré D, Dumont F, Honoré C, Dartigues P, Stoclin A, Malka D, Boige V, Ducreux M. Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. Eur J Cancer 2014 Jan;50(2):332–340.
  3.Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 2012;30:2449—2456.[11]
  4.Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 2009; 27:6237—6242.
  5.Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010;28:63—68.
  6.Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008;15:2426—2432.
  7.Glehen O, Gilly FN, Arvieux C, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 2010;17(9):2370—2377.
  8.Glehen O, Passot G, Villeneuve L, et al. (2014) GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multi-center phase III study. BMC Cancer 14:183CrossRef PubMed PubMedCentral
  9.Mulier S, Claes JP, Dierieck V, Amiel JO, Pahaut JP, Marcelis L, Bastin F (2012) Survival benefit of adding hyperthermic IntraPEritoneal chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence. Curr Pharm Des 18:3793–3803CrossRef PubMed
  10.Maggiori L, Elias D (2010) Curative treatment of colorectal peritoneal carcinomatosis: current status and future trends. Eur J Surg Oncol 36:599–603CrossRef PubMed
  11.Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221(1):29–42CrossRef PubMed PubMedCentral
  12.Smeenk RM, Verwaal VJ, Zoetmulder FA (2007) Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg 94:1408–1414CrossRef PubMed
  13.Moran BJ (2006) Establishment of a peritoneal malignancy treatment center in the United Kingdom. Eur J Surg Oncol 32:614–618CrossRef PubMed
  14.Mohamed F, Moran BJ. Morbidity and mortality with cytoreductive surgery and intraperitoneal chemotherapy: the importance of a learning curve. Cancer J 2009 May-Jun; 15(3):196–199. Review.
  15.Mohamed F, Cecil T, Moran B, Sugarbaker P. A new standard of care for the management of peritoneal surface malignancy. Curr Oncol 2011 Apr. 18(2):e84–e96.
  16.Goéré D, Malka D, Tzanis D, Gava V, Boige V, Eveno C, Maggiori L, Dumont F, Ducreux M, Elias D. ‘Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy?’ Ann Surg 2013 Jun; 257(6):1065–1071.
  17.Tomlinson J, Jarnagin W, DeMatteo R, Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan M, Blumgart L, D'Angelica M (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. JCO 25(29):4575–4580CrossRef
  18.Goéré D, Souadka A, Faron M, Cloutier AS, Viana B, Honoré C, Dumont F, Elias D. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: A comparative study. Ann Surg Oncol 2015 Jan 29.
  19.Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyper-thermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg 2009;249:900—907.
  20.Glehen O, Gilly FN, Boutitie F, et al. Toward curative treatment of peritoneal carcinomatosis from non-ovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer 2010;116:5608—5618.
  21.Helm CW, Richard SD, Pan J, et al. (2010) Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry. Int J Gynecol Cancer 20(1):61–69CrossRef PubMed
  22.Bakrin N, Bereder JM, Decullier E, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicenter retrospective cohort study of 566 patients. Eur J Surg Oncol 2013;39:1435—1443.
  23.P. Dubé, L. Sideris, C. Law, L. Mack, E. Haase, C. Giacomantonio, A. Govindarajan, M.K. Krzyzanowska, P. Major, Y. McConnell, W. Temple, R. Younan, J.A. McCart Guidelines on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms. Curr Oncol. 2015 April; 22(2): PMC4399618
  
• 作者单位：Aditi Bhatt (1)
  Sanket Mehta (2)
  Ramakrishnan Ayloor Seshadri (3)
  Kayomarz Sethna (4)
  Shabber Zaveri (5)
  Firoz Rajan (6)
  Vikas Mahajan (7)
  Shivendra Singh (8)
  E. Hemanth Raj (3)
  Paul H. Sugarbaker (9)
  
  1. Department of Surgical Oncology, Fortis Hospital, 154/9 Bannerghatta road, Opposite IIM-Bangalore, Bangalore, -560076, India
  2. Department of Surgical Oncology, Saifee Hospital, Mumbai, India
  3. Department of Surgical Oncology, Cancer Institute (WIA), Chennai, India
  4. Department of General Sugery, Sion Hospital Mumbai, Mumbai, India
  5. Department of Surgical Oncology, Manipal Hospital, Bangalore, India
  6. Department of Surgical Oncology, Kovai Medical Centre, Coimbatore, India
  7. Department of Surgical Oncology, Apollo Hospital, Chennai, India
  8. Department of GI Oncology, Rajiv Gandhi Cancer Centre, New Delhi, India
  9. Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC, USA
  
• 刊物主题：Surgical Oncology; Oncology; Surgery;
• 出版者：Springer India
• ISSN：0976-6952

文摘

Worldwide, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been used for nearly 3 decades to treat peritoneal metastases (PM), improve quality of life, and prolong survival substantially in selected patients. In India, the use of the combined modality of treatment dates back a decade with majority of the efforts taking place within the last 5 years. The first PSOGI workshop (India) held in April 2015, at Bangalore, India offered an opportunity for Indian surgeons performing CRS and HIPEC to share their experience. To study the methodologies of CRS and HIPEC (hospital set up, equipment, training and surgical background) as well as the outcomes in terms of perioperative morbidity and mortality and short and long term survival of patients treated in India, Indian surgeons who had treated at least 10 patients with this combined modality were invited to present their experience. Data collection was retrospective. Analysis of the pooled data was carried out. Eight surgeons treated 384 patients with CRS and HIPEC over a period of 10 years. The commonest primary sites were ovary (as first line therapy n = 124), followed by appendix, including pseudomyxoma peritonei (n = 99), colorectum (n = 77), recurrent ovary (as second line therapy, n = 33), stomach (n = 15), primary peritoneal cancer (n = 10), peritoneal mesothelioma (n = 9) and rare tumors in 17 patients. The weighted mean PCI for all 384 patients was 18.25. 349/384 patients (90.88 %) had a complete cytoreduction (completeness of cytoreduction score of CC-0/1). Grade 3–5 complications developed in 108 patients (27.34 %) and 30 day mortality occurred in 28 (7.29 %) patients. This study showed that CRS and HIPEC can be performed with an acceptable morbidity and mortality in Indian patients. Most of the surgeons are on the learning curve and further improvement in these outcomes is expected over a period of time. Pooling of data related to both common and rare peritoneal cancers would be useful in knowing the disease behavior, response to treatment and outcomes in Indian patients. The 2015 PSOGI meeting provided a unique platform for data presentation with feedback from international experts in the field of peritoneal surface oncology. Future meetings are planned to expand the evaluation of Indian data and progress.